Cymabay Therapeutics Inc
Officers & Directors
Sujal Shah, age 50, has served as President and Chief Executive Officer since November 2017, previously holding interim CEO and CFO positions. He has prior experience at Citigroup Inc. and Credit Suisse and holds an MBA from Carnegie Mellon University and degrees in Biomedical Engineering from Northwestern University. Charles A. McWherter, Ph.D., age 69, has been President of Research and Development and Chief Scientific Officer since November 2022, having served as Chief Scientific Officer since 2013. His prior roles include positions at Pfizer Inc. and Sugen, Inc., and he holds a Ph.D. from Cornell University. Paul T. Quinlan, age 61, has been General Counsel and Chief Compliance Officer since October 2020. He previously held similar roles at TerraVia Holdings, Inc., Metabolex, Inc., and Maxygen, Inc., and holds a law degree from Columbia University Law School and an M.Sc. from the University of Toronto. Harish Shantharam, age 42, has served as Chief Financial Officer since May 2023. He was previously a senior finance advisor at Eikon Therapeutics and held various finance roles at Gilead Sciences, Inc. and Amgen. He holds an MBA from UCLA Anderson School of Management, a graduate degree from the University of Texas at Arlington, and is a CFA charterholder. Klara Dickinson, age 57, has been Chief Regulatory and Quality Assurance Officer since October 2020. She previously held senior regulatory roles at Anthera Pharmaceuticals, Inc., Hyperion Therapeutics Inc., CoTherix, Inc., Scios, Inc., and DEY Laboratories, a subsidiary of Mylan, Inc.
Cymabay Therapeutics Inc currently has 68 employees.
News about Cymabay Therapeutics Inc Key Personnel |
CymaBay Therapeutics Inc (Nasdaq: CBAY) has recently announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Seladelpar, a potential treatment for Primary Biliary Cholangitis (PBC). This comes after the company submitted applications for Seladelpar to the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) and the United States Food and Drug Administration (FDA).
The acceptance of the MAA by the EMA is a significant milestone for CymaBay, as it signals the beginning of the regulatory review process in Europe. Primary Biliary Cholangitis is a chronic, autoimmune liver disease that affects the bile ducts, leading to inflam...
|
|
